| abstract |
The present invention relates to a novel hepatitis C prophylaxis or treatment composition for regulating replication enzyme phosphorylation, and more particularly, to prevent or treat hepatitis C through a novel PRK2 inhibitor discovered through structural modeling. Concomitant administration of Hsp90 inhibitors can effectively prevent or treat hepatitis C, particularly interferon-insensitive hepatitis C. |